China's Adenovirus Type 5 Vector Vaccine Very Effective Against COVID-19

China-based CanSino Biologics Inc. announced on December 24, 2021, that The Lancet published its Phase III clinical trial results on the safety and efficacy of its Recombinant Novel Coronavirus Vaccine Convidecia™.

The analysis showed that a single dose of Convidecia is efficacious and safe, with an efficacy of 96% in preventing severe COVID-19 disease.

And an overall efficacy of 63.7% 14 days post-vaccination for healthy adults aged 18 and above, without any reported vaccine-related serious adverse events.

This Phase III clinical trial is a global multicenter, randomized, double-blind, placebo-controlled study in Argentina, Chile, Mexico, Pakistan, and Russia and enrolled about 45,000 volunteers.

To date, Convidecia received approvals in at least ten markets, including China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia, and Malaysia.

"CanSinoBIO remains committed to our mission of providing affordable, timely, and mass immune protection to the global population, and will continue to collaborate with partners in the public and private sectors to improve vaccine access and have more people benefit from our technology breakthroughs," said Dr. Xuefeng YU, Chairman and CEO of CanSinoBIO, in a press release.

The Company has also seen encouraging data in the trial of a booster dose of Convidecia for people inoculated with two doses of inactivated vaccines.

Data showed that administering a booster dose of Convidecia could result in an approximately 78-fold increase in neutralizing antibody level 14 days post-vaccination. 

Additionally, administering a homologous booster dose of Convidecia six months after the prime immunization could result in a 7-fold increase in neutralizing antibody level.

In addition, CanSinoBIO has made notable progress in developing its Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for inhalation.

Studies showed that a combination of an intramuscular and inhaled regimen of Convidecia offers more robust protection than a single intramuscular dose.

The neutralizing antibody level 28 days after the mixed regimen was four times higher than a single intramuscular injection, which could remain at a high level after six months.  

CanSinoBIO was incorporated in Tianjin, China, during 2009 and commits to research, production, and commercialization of innovative vaccines for China and global public health security.